Alessandro Trentini

Dr. Alessandro Trentini

University of Ferrara, department of Biomedical and Specialist Surgical Sciences
orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
Donato GemmatiDonato Gemmati
Donato Gemmati
Katia VaraniKatia Varani
Katia Varani
BBBarbara Bramanti
Barbara Bramanti
RPRoberta Piva
Roberta Piva
GBGloria Bonaccorsi
Gloria Bonaccorsi
Tiziana BelliniTiziana Bellini
Tiziana Bellini
Gender medicine is the first step of personalized medicine and patient-centred care, an essential development to achieve the standard goal of a holistic approach to patients and diseases. By addressing the interrelation and integration of biological markers (i.e., sex) with indicators of psychological/cultural behaviour (i.e., gender), gender medicine represents the crucial assumption for achieving the personalized health-care required in the third millennium. However, ‘sex’ and ‘gender’ are often misused as synonyms, leading to frequent misunderstandings in those who are not deeply involved in the field. Overall, we have to face the evidence that biological, genetic, epigenetic, psycho-social, cultural, and environmental factors mutually interact in defining sex/gender differences, and at the same time in establishing potential unwanted sex/gender disparities. Prioritizing the role of sex/gender in physiological and pathological processes is crucial in terms of efficient prevention, clinical signs’ identification, prognosis definition, and therapy optimization. In this regard, the omics-approach has become a powerful tool to identify sex/gender-specific disease markers, with potential benefits also in terms of socio-psychological wellbeing for each individual, and cost-effectiveness for National Healthcare systems. “Being a male or being a female” is indeed important from a health point of view and it is no longer possible to avoid “sex and gender lens” when approaching patients. Accordingly, personalized healthcare must be based on evidence from targeted research studies aimed at understanding how sex and gender influence health across the entire life span. The rapid development of genetic tools in the molecular medicine approaches and their impact in healthcare is an example of highly specialized applications that have moved from specialists to primary care providers (e.g., pharmacogenetic and pharmacogenomic applications in routine medical practice). Gender medicine needs to follow the same path and become an established medical approach. To face the genetic, molecular and pharmacological bases of the existing sex/gender gap by means of omics approaches will pave the way to the discovery and identification of novel drug-targets/therapeutic protocols, personalized laboratory tests and diagnostic procedures (sex/gender-omics). In this scenario, the aim of the present review is not to simply resume the state-of-the-art in the field, rather an opportunity to gain insights into gender medicine, spanning from molecular up to social and psychological stances. The description and critical discussion of some key selected multidisciplinary topics considered as paradigmatic of sex/gender differences and sex/gender inequalities will allow to draft and design strategies useful to fill the existing gap and move forward.

5 June 2013 in Molecular and Cellular Biochemistry
Verified
Journal Article
Closed access
PDF file
Roberta RizzoRoberta Rizzo
Roberta Rizzo
Alessandro TrentiniAlessandro Trentini
Alessandro Trentini
Daria BortolottiDaria Bortolotti
Daria Bortolotti
Maria Cristina ManfrinatoMaria Cristina Manfrinato
Maria Cristina Manfrinato
ARAntonella Rotola
Antonella Rotola
Tiziana BelliniTiziana Bellini
Tiziana Bellini

23 August 2012 in Multiple Sclerosis Journal
Verified
Journal Article
Open access
MKMichael Khalil
Michael Khalil
CEC Enzinger
C Enzinger
CLC Langkammer
C Langkammer
SRS Ropele
S Ropele
AMA Mader
A Mader
CTCe Teunissen
Ce Teunissen
Axonal damage is considered a major cause of disability in multiple sclerosis (MS) and may start early in the disease. Specific biomarkers for this process are of great interest. To study if cerebrospinal fluid (CSF) biomarkers for axonal damage reflect and predict disease progression already in the earliest stages of the disease, that is, in clinically isolated syndrome (CIS). We assessed CSF levels of neurofilament heavy (NFH), neurofilament light (NFL) and N-acetylaspartate (NAA) in 67 patients with CIS and 18 controls with neuropsychiatric diseases of non-inflammatory aetiology (NC). Patients with CIS underwent baseline magnetic resonance imaging (MRI) at 3T, and a follow-up MRI after 1 year was obtained in 28 of them. Compared with NC, patients with CIS had higher NFH (p=0.05) and NFL (p<0.001) levels. No significant group differences were found for NAA. Patients’ NFH levels correlated with physical disability (r=0.304, p<0.05) and with change in brain volume over 1 year of follow-up (r=-0.518, p<0.01) but not with change in T2 lesion load. Our results confirm increased neurofilament levels already in CIS being related to the level of physical disability. The association of NFH levels with brain volume but not lesion volume changes supports the association of these markers with axonal damage.

28 May 2021 in Diagnostics
Verified
Journal Article
Open access
PDF file
Marco ZuinMarco Zuin
Marco Zuin
Carlo CervellatiCarlo Cervellati
Carlo Cervellati
Alessandro TrentiniAlessandro Trentini
Alessandro Trentini
APAngelina Passaro
Angelina Passaro
VRValentina Rosta
Valentina Rosta
GZGiovanni Zuliani
Giovanni Zuliani
Background: A wealth of experimental and epidemiological evidence suggest that Apolipoprotein A-I (ApoA-I), the main protein constituent of high-density lipoprotein (HDL), may protect against Alzheimer disease (AD). To investigate this potential role, we conducted a meta-analysis of the published studies on the relationship between serum ApoA-I and AD occurrence. Methods: We screened MEDLINE, EMBASE, Web of Science, and Scopus, for cross-sectional studies published from inception to 1 March 2021, comparing the ApoA-I serum levels between patients with AD and cognitively normal controls. Results: From an initial screening of 245 articles, 5 studies, including 397 AD patients (mean age 75.0 years, 234 females) and 367 controls (mean age 69.2 years, 182 females), met the inclusion criteria. Compared to healthy controls, AD subjects had a lower ApoA-I serum level. The pooled weighted mean difference from a random-effects model was −0.31 g/L (p < 0.0001) (95% Confidence Interval: [−0.62–0.01], with high heterogeneity (I2 = 100%). The Egger’s test confirmed an absence of publication bias (t = 0.62, p = 0.576). Conclusions: Our study showed that AD patients present lower serum levels of ApoA-I compared to cognitively normal individuals. Further studies on large population samples are required to support this finding.

1 January 2015 in Vascular Pharmacology
Verified
Journal Article
Closed access
Federico CarboneFederico Carbone
Federico Carbone
NVNicolas Vuilleumier
Nicolas Vuilleumier
MBMaria Bertolotto
Maria Bertolotto
FBFabienne Burger
Fabienne Burger
KGKatia Galan
Katia Galan
Fabrizio MontecuccoFabrizio Montecucco
Fabrizio Montecucco

9 January 2021 in Oxidative Medicine and Cellular Longevity
Verified
Journal Article
Open access
PDF file
FZFrancesca Zimetti
Francesca Zimetti
MAMaria Pia Adorni
Maria Pia Adorni
JMJudit Marsillach
Judit Marsillach
CMCinzia Marchi
Cinzia Marchi
Alessandro TrentiniAlessandro Trentini
Alessandro Trentini
Carlo CervellatiCarlo Cervellati
Carlo Cervellati
The protein composition of high‐density lipoprotein (HDL) is extremely fluid. The quantity and quality of protein constituents drive the multiple biological functions of these lipoproteins, which include the ability to contrast atherogenesis, sustained inflammation, and toxic effects of reactive species. Several diseases where inflammation and oxidative stress participate in the pathogenetic process are characterized by perturbation in the HDL proteome. This change inevitably affects the functionality of the lipoprotein. An enlightening example in this frame comes from the literature on Alzheimer’s disease (AD). Growing lines of epidemiological evidence suggest that loss of HDL‐associated proteins, such as lipoprotein phospholipase A2 (Lp‐PLA2), glutathione peroxidase‐3 (GPx‐3), and paraoxonase‐1 and paraoxonase‐3 (PON1, PON3), may be a feature of AD, even at the early stage. Moreover, the decrease in these enzymes with antioxidant/defensive action appears to be accompanied by a parallel increase of prooxidant and proinflammatory mediators, in particular myeloperoxidase (MPO) and serum amyloid A (SAA). This type of derangement of balance between two opposite forces makes HDL dysfunctional, i.e., unable to exert its “natural” vasculoprotective property. In this review, we summarized and critically analyzed the most significant findings linking HDL accessory proteins and AD. We also discuss the most convincing hypothesis explaining the mechanism by which an observed systemic occurrence may have repercussions in the brain.